Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Pelthos Therapeutics (PTHS) Preferred Shares (2022 - 2023)

Pelthos Therapeutics has reported Preferred Shares over the past 1 years, most recently at $60.0 for Q4 2023.

For Q4 2023, Preferred Shares changed N/A year-over-year to $60.0; the TTM value through Dec 2023 reached $60.0, changed N/A, while the annual FY2023 figure was $60.0, N/A changed from the prior year.
Preferred Shares for Q4 2023 was $60.0 at Pelthos Therapeutics.
Over five years, Preferred Shares peaked at $60.0 in Q4 2023 and troughed at $60.0 in Q4 2023.